Study design (if review, criteria of inclusion for studies)
Interventional - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment
Participants
Cystic Fibrosis|Bronchiectasis - 18 Years and older (Adult, Older Adult)
Interventions
Drug: BI 1291583|Drug: Placebo
Outcome measures
Occurrence of Treatment emergent Adverse Events (TEAEs) up to 16 weeks from first drug administration|Relative change from baseline in neutrophil elastase (NE) activity in sputum at week 8 after first drug administration|Area under the concentration-time curve of the analyte in plasma over a uniform dosing interval (AUCÏ) for the first dose|Maximum measured concentration of the analyte in plasma (Cmax) for the first dose|Area under the concentration-time curve of the analyte in plasma at steady state over a uniform dosing interval (AUCÏ,ss)|Maximum measured concentration of the analyte in plasma (Cmax) at steady state (Cmax,ss)